Lucid Diagnostics Inc. logo

Lucid Diagnostics (LUCD) stock

LUCD · Lucid Diagnostics Inc. · NASDAQ

$0.38-0.02 (-3.88%)today
Website
Market cap
$77.7M
Shares out
205.0M
Open
$0.3842
Prev close
$0.3944
VWAP
$0.3743
52-week range6% up the range
$0.3033$1.62

Today $0.3572 - $0.3928

What is the latest news on LUCD stock?

LUCD fell 3.88% to $0.3791 on Nov 20, 2026. No LUCD story in the last two days; the most recent is below.

PRago
PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results

Lucid Diagnostics' EsoGuard® now fully reimbursed by Medicare nationwideVeris Health achieved implantable physiological monitor design freeze and initiated 90-day GLP animal study ahead of early 2027 FDA submissionPAVmed engaged with FDA on PortIO and OcterisConference call and webcast to be held today, November 13, at 8:30 AM ESTNEW YORK, Nov. 13, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), Veris Health Inc. ("Ve

All LUCD news
Price$0.38-0.02 (-3.88%)
02:30 PM08:45 PM

When does Lucid Diagnostics report earnings?

Lucid Diagnostics last reported on Nov 12, 2026, the date it announced on Oct 29, 2026. Before that it reported on Aug 13, 2026 and May 14, 2026. On that schedule the next report would come around mid February 2027, with the date usually announced about 2 weeks ahead.

LUCD earnings history

Who owns the most LUCD stock?

Alyeska Investment Group, L.P. was the largest reported holder of LUCD at the end of Q2 2026, with 8,856,844 shares worth $9.5 million. Next came BlackRock, Inc. ($9.0 million) and Vanguard Capital Management LLC ($7.0 million). In all, 116 institutions reported $65.7 million of LUCD in their 13F filings.

All LUCD fund holders

Are insiders buying or selling LUCD?

No LUCD insider has reported a purchase or sale in the last 90 days. The last trade on file: Dennis Matheis bought $245K, reported on May 21, 2026.

LUCD insider trades

Financial highlights

Full financials
Revenue, TTM
$5.44M
Revenue growth
+23.6%
Net income, TTM
-$48.54M
Net margin
-892.8%
Free cash flow, TTM
-$51.83M
Cash
$17.99M

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

Latest news

25 items
News · 26 weeks24+17%
2026-05-31: 02026-06-07: 02026-06-14: 02026-06-21: 12026-06-28: 02026-07-05: 02026-07-12: 02026-07-19: 02026-07-26: 22026-08-02: 22026-08-09: 42026-08-16: 02026-08-23: 02026-08-30: 02026-09-06: 02026-09-13: 02026-09-20: 22026-09-27: 02026-10-04: 02026-10-11: 12026-10-18: 32026-10-25: 22026-11-01: 32026-11-08: 42026-11-15: 02026-11-22: 0
2026-05-312026-11-22
Mix1590d
  • Other5(33%)
  • SEC Filings5(33%)
  • Earnings4(27%)
  • Dividends1(7%)
Activity · 52 weeks6845 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Lucid Diagnostics Inc. (LUCD) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 10 wire items for LUCD, including 4 press releases and news items, 4 earnings updates and 2 SEC filings. The most recent was published Nov 13, 2026.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

LUCD FAQ

10 questions
  • What does Lucid Diagnostics Inc. do?
    Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of...
  • What is LUCD revenue?
    Lucid Diagnostics Inc. (LUCD) reported $5.44M of revenue for the twelve months ended Sep 30, 2026. That is up 23.6% from the year before. Revenue for fiscal 2025 was $4.71M.
  • Is LUCD profitable?
    No. Lucid Diagnostics Inc. reported a net loss of $48.54M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does LUCD have?
    Lucid Diagnostics Inc. reported $17.99M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • Where does LUCD stock trade?
    Lucid Diagnostics Inc. (LUCD) is listed on NASDAQ.
  • What sector and industry is LUCD in?
    Lucid Diagnostics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.
  • When did Lucid Diagnostics Inc. go public?
    Lucid Diagnostics Inc. (LUCD) completed its IPO in 2021.
  • What are analysts saying about LUCD?
    Lucid Diagnostics Inc. has had 6 recent analyst actions on file. The most recent action was from Ascendiant Capital: Buy with a $16.00 price target on 2021-12-27. Recent price targets range from $13.00 to $21.00.
  • What companies are similar to LUCD?
    Notable peers in the same industry include BSX (Boston Scientific Corporation), RMD (ResMed Inc.), MDLN (Medline Inc.), DXCM (DexCom Inc.), MMM (3M Company). Compare LUCD side-by-side with any of them on Quantisnow.
  • How can I track LUCD on Quantisnow?
    Quantisnow aggregates Lucid Diagnostics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LUCD to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change